Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

1.

Analysis of complete response by MRI following neoadjuvant chemotherapy predicts pathological tumor responses differently for molecular subtypes of breast cancer.

Hayashi Y, Takei H, Nozu S, Tochigi Y, Ichikawa A, Kobayashi N, Kurosumi M, Inoue K, Yoshida T, Nagai SE, Oba H, Tabei T, Horiguchi J, Takeyoshi I.

Oncol Lett. 2013 Jan;5(1):83-89. Epub 2012 Oct 30.

2.

Accuracy of magnetic resonance imaging for predicting pathological complete response of breast cancer after neoadjuvant chemotherapy: association with breast cancer subtype.

Fukuda T, Horii R, Gomi N, Miyagi Y, Takahashi S, Ito Y, Akiyama F, Ohno S, Iwase T.

Springerplus. 2016 Feb 24;5:152. doi: 10.1186/s40064-016-1800-x. eCollection 2016.

3.

MRI evaluation of pathologically complete response and residual tumors in breast cancer after neoadjuvant chemotherapy.

Chen JH, Feig B, Agrawal G, Yu H, Carpenter PM, Mehta RS, Nalcioglu O, Su MY.

Cancer. 2008 Jan 1;112(1):17-26. Erratum in: Cancer. 2008 Apr 1;112(7):1642. Feig, Byon [corrected to Feig, Byron].

4.

Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer. Translational Breast Cancer Research Consortium trial 017.

De Los Santos JF, Cantor A, Amos KD, Forero A, Golshan M, Horton JK, Hudis CA, Hylton NM, McGuire K, Meric-Bernstam F, Meszoely IM, Nanda R, Hwang ES.

Cancer. 2013 May 15;119(10):1776-83. doi: 10.1002/cncr.27995. Epub 2013 Feb 21.

5.

Diffusion-weighted imaging in assessing pathological response of tumor in breast cancer subtype to neoadjuvant chemotherapy.

Liu S, Ren R, Chen Z, Wang Y, Fan T, Li C, Zhang P.

J Magn Reson Imaging. 2015 Sep;42(3):779-87. doi: 10.1002/jmri.24843. Epub 2015 Jan 8.

PMID:
25580585
6.

Diagnostic performance of magnetic resonance imaging for assessing tumor response in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy is associated with molecular biomarker profile.

Kuzucan A, Chen JH, Bahri S, Mehta RS, Carpenter PM, Fwu PT, Yu HJ, Hsiang DJ, Lane KT, Butler JA, Feig SA, Su MY.

Clin Breast Cancer. 2012 Apr;12(2):110-8. doi: 10.1016/j.clbc.2012.01.009.

7.

Effect of breast cancer phenotype on diagnostic performance of MRI in the prediction to response to neoadjuvant treatment.

Bufi E, Belli P, Di Matteo M, Terribile D, Franceschini G, Nardone L, Petrone G, Bonomo L.

Eur J Radiol. 2014 Sep;83(9):1631-8. doi: 10.1016/j.ejrad.2014.05.002. Epub 2014 May 16.

PMID:
24938669
8.

Accuracy of breast magnetic resonance imaging in predicting pathologic response in patients treated with neoadjuvant chemotherapy.

De Los Santos J, Bernreuter W, Keene K, Krontiras H, Carpenter J, Bland K, Cantor A, Forero A.

Clin Breast Cancer. 2011 Oct;11(5):312-9. doi: 10.1016/j.clbc.2011.06.007. Epub 2011 Aug 10.

PMID:
21831721
9.

MRI staging after neoadjuvant chemotherapy for breast cancer: does tumor biology affect accuracy?

McGuire KP, Toro-Burguete J, Dang H, Young J, Soran A, Zuley M, Bhargava R, Bonaventura M, Johnson R, Ahrendt G.

Ann Surg Oncol. 2011 Oct;18(11):3149-54. doi: 10.1245/s10434-011-1912-z. Epub 2011 Sep 27.

PMID:
21947592
10.

FDG PET/CT during neoadjuvant chemotherapy may predict response in ER-positive/HER2-negative and triple negative, but not in HER2-positive breast cancer.

Koolen BB, Pengel KE, Wesseling J, Vogel WV, Vrancken Peeters MJ, Vincent AD, Gilhuijs KG, Rodenhuis S, Rutgers EJ, Vald├ęs Olmos RA.

Breast. 2013 Oct;22(5):691-7. doi: 10.1016/j.breast.2012.12.020. Epub 2013 Feb 12.

PMID:
23414930
11.

Relationship between intrinsic subtypes and tumor responses to neoadjuvant chemotherapy in patients with locally advanced breast cancer.

Ooe A, Takahara S, Sumiyoshi K, Yamamoto H, Kawai J, Shiba E.

Breast Dis. 2012;34(1):9-17. doi: 10.3233/BD-130345.

PMID:
23507670
12.

Evaluation with 3.0-T MR imaging: predicting the pathological response of triple-negative breast cancer treated with anthracycline and taxane neoadjuvant chemotherapy.

Kim MJ, Kim EK, Park S, Moon HJ, Kim SI, Park BW.

Acta Radiol. 2015 Sep;56(9):1069-77. doi: 10.1177/0284185114548507. Epub 2014 Sep 16.

PMID:
25228161
13.

Can Routine Imaging After Neoadjuvant Chemotherapy in Breast Cancer Predict Pathologic Complete Response?

Schaefgen B, Mati M, Sinn HP, Golatta M, Stieber A, Rauch G, Hennigs A, Richter H, Domschke C, Schuetz F, Sohn C, Schneeweiss A, Heil J.

Ann Surg Oncol. 2016 Mar;23(3):789-95. doi: 10.1245/s10434-015-4918-0. Epub 2015 Oct 14.

PMID:
26467456
14.

Magnetic resonance examination to predict pathological complete response following neoadjuvant chemotherapy: when is it appropriate for HER2-positive and triple-negative breast cancers?

Okamoto S, Yamada T, Kanemaki Y, Kojima Y, Tsugawa K, Nakajima Y.

Breast Cancer. 2016 Sep;23(5):789-96. doi: 10.1007/s12282-015-0642-7. Epub 2015 Oct 5.

PMID:
26437647
15.

Accuracy of MRI for treatment response assessment after taxane- and anthracycline-based neoadjuvant chemotherapy in HER2-negative breast cancer.

Charehbili A, Wasser MN, Smit VT, Putter H, van Leeuwen-Stok AE, Meershoek-Klein Kranenbarg WM, Liefers GJ, van de Velde CJ, Nortier JW, Kroep JR.

Eur J Surg Oncol. 2014 Oct;40(10):1216-21. doi: 10.1016/j.ejso.2014.07.036. Epub 2014 Aug 8.

PMID:
25150151
16.

Association between Pathological Complete Response and Outcome Following Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer Patients.

Luangdilok S, Samarnthai N, Korphaisarn K.

J Breast Cancer. 2014 Dec;17(4):376-85. doi: 10.4048/jbc.2014.17.4.376. Epub 2014 Dec 26.

17.

Evaluating the response of neoadjuvant chemotherapy for treatment of breast cancer: are tumor biomarkers and dynamic contrast enhanced MR images useful predictive tools?

Zhang Z, Zhang W, Jin Y, Wang H, Gu F, Zhou J, Lao Z, Xu Z, Tang F, Zou L, Tang W, Lu R, Zou Q.

J Thorac Dis. 2014 Jun;6(6):785-94. doi: 10.3978/j.issn.2072-1439.2014.04.28.

18.

Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment.

Chang HR, Glaspy J, Allison MA, Kass FC, Elashoff R, Chung DU, Gornbein J.

Cancer. 2010 Sep 15;116(18):4227-37. doi: 10.1002/cncr.25309.

19.

Magnetic Resonance Imaging after Completion of Neoadjuvant Chemotherapy Can Accurately Discriminate between No Residual Carcinoma and Residual Ductal Carcinoma In Situ in Patients with Triple-Negative Breast Cancer.

Park S, Yoon JH, Sohn J, Park HS, Moon HJ, Kim MJ, Kim EK, Kim SI, Park BW.

PLoS One. 2016 Feb 11;11(2):e0149347. doi: 10.1371/journal.pone.0149347. eCollection 2016.

20.

Pathological responses and survival of patients with human epidermal growth factor receptor 2-positive breast cancer who received neoadjuvant chemotherapy including trastuzumab.

Ohzawa H, Sakatani T, Niki T, Yasuda Y, Hozumi Y.

Breast Cancer. 2014 Sep;21(5):563-70. doi: 10.1007/s12282-012-0424-4. Epub 2012 Oct 30.

PMID:
23108629

Supplemental Content

Support Center